For instance, the treatments of utilizing monoclonal antibodies to neutralize single-antigens like CTLA-4, PD-1, and PD-L1 exhibited modest results in ovarian cancer patients with a median response rate of around 15% [15,18,19,20,21]. This evidence concerns the gene PDCD1 and ovarian cancer.